CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Betamethasone Dipropionate

· ingredient betamethasoneCorticosteroids· BETAMETHASONE DIPROPIONATE .5 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$0.16833
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per GM — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other betamethasone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.

ProductNADAC / GMvs this
Clobezin$0.19868+$0.03040
Betamethasone Dipropionate$0.30015+$0.13180
betamethasone dipropionate$0.41588+$0.24760
Betamethasone dipropionate$0.45908+$0.29080
Betamethasone Dipropionate$0.53787+$0.36950
betamethasone valerate$0.57225+$0.40390
DIPROLENE$0.61496+$0.44660
Betamethasone Valerate$0.73220+$0.56390

Medicare Part D coverage · CY2026

On 327 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 50% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.